RESULTS At @ weeks , the continuous administration group displayed decreases in BASDAI from @ to @ , in ASDAS from @ to @ , and in hs-CRP levels from @ to @ mg/l ; the intermittent administration group exhibited decreases in BASDAI from @ to @ , in ASDAS from @ to @ , and hs-CRP from @ to @ mg/l ( p < @ ) .